Q-omics provides the consensus-scored LINC01589 profile across patient tissues and cancer cell-line models. LINC01589 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, LINC01589 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, LINC01589 RNA expression shows 12,664 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCEC, KIRC, and TGCT as cancer lineages where LINC01589 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01589 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01589 survival associations across molecular data types. LINC01589 RNA expression shows survival associations in the most cancer types (27). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01589 RNA expression–survival associations across cancer types. High LINC01589 expression shows unfavorable associations in KIRC, THCA, LIHC and KIRP, but favorable associations in UCEC and BLCA. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for LINC01589 RNA expression.
This table summarizes LINC01589 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01589. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01589 shows lower tumor expression in KIRC, THCA, KICH, UCEC, BRCA and BLCA. The KIRC box plot shows higher LINC01589 RNA expression in normal versus tumor tissue (log2 FC = −1.258, t-test p < 0.001).
This table shows molecular features associated with LINC01589 in patient tissues and cancer cell lines. In patient samples, LINC01589 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
